RxDoctor Payments Data

Krutika Patel

Family · Washington, DCNPI 1821597634

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.9% of the total across 98 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations.

$2,137in general payments, 2019–2025

Across 98 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$292
  • Novo Nordisk$284
  • Amgen$280
  • AbbVie$257
  • Astellas Pharma US Inc$188
  • Lilly USA, LLC$155
  • plus $681 from 17 others

What the payments were for

  • Food & beverage$2,07197%
  • Education$663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,137 in reported general payments places this provider in the 85th percentile of 392 family providers in District of Columbia.

See all family providers in District of Columbia

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate14$11,970
Rosuvastatin Calcium46$981
Metoprolol Succinate32$706
Atorvastatin Calcium47$558
Levothyroxine Sodium44$492
Losartan Potassium41$484
Simvastatin13$365
Olmesartan Medoxomil13$275
Tamsulosin Hcl11$231
Pantoprazole Sodium21$221
Lisinopril23$215
Famotidine11$195
Metformin Hcl25$171
Amlodipine Besylate38$169
Trazodone Hcl21$168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$149$11,97014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 392 family providers in District of Columbia.

Other family in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →